kabutan

SymBio Pharmaceuticals Limited(4582) Summary

4582
TSE Growth
SymBio Pharmaceuticals Limited
86
JPY
-2
(-2.27%)
Jan 29, 3:06 pm JST
0.56
USD
Jan 29, 1:06 am EST
Result
PTS
outside of trading hours
86.8
Jan 29, 3:02 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.86
Yield
ー%
Margin Trading Ratio
11,263.25
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
89 JPY 0.58 USD
Previous Close Jan 28
88 JPY 0.57 USD
High Jan 29, 9:00 am
89 JPY 0.58 USD
Low Jan 29, 9:03 am
85 JPY 0.55 USD
Volume
1,112,600
Trading Value
0.10B JPY 0.63M USD
VWAP
86.8 JPY 0.57 USD
Minimum Trading Value
8,600 JPY 56 USD
Market Cap
5.12B JPY 0.03B USD
Number of Trades
240
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
262
1-Year High Sep 17, 2025
3,139
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 4,870,400
Jan 16, 2026 0 4,444,400
Jan 9, 2026 0 4,237,400
Dec 26, 2025 0 4,149,400
Dec 19, 2025 0 3,845,800
Company Profile
SymBio Pharmaceuticals Limited specializes in three areas: cancer, hematology, and pain management. The company also commercializes new drug candidates from other companies.
Sector
Pharmaceuticals
SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on rare diseases, primarily in the fields of oncology, hematology, and viral infections. The company advances the development of compounds that have already established proof of concept in humans. Utilizing its unique discovery network and evaluation expertise, SymBio conducts initial screenings through its in-house specialist staff, followed by rigorous evaluations from experienced external experts before finalizing potential in-licensing candidates. By adopting a "labo-less fab-less" strategy to minimize fixed costs, the company concentrates on high-value-added activities while outsourcing routine development tasks. SymBio's pipeline includes drugs such as Treakisym, rigosertib, and brincidofovir, promoting new drug development in areas with high unmet medical needs. While the company has primarily focused its business operations in Japan and Asia, it now aims to expand globally to enhance its business value.